Adherium operates a digital health platform monitoring respiratory medication adherence through connected inhaler sensors, earning subscription revenue from US Medicare reimbursement. At A$0.005 versus fair value A$0.0079, the stock offers 58% upside. The key tension is operational momentum—patient numbers growing 103% quarter-on-quarter—against severe capital distress requiring another fundraise within six months, with existing shareholders facing 180% dilution to fund the scale-up.

Best fit: High-risk growth and thematic investors. The operational momentum (103% quarterly revenue growth, partnerships activating) validates the growth trajectory, while regulatory tailwinds and demographic shifts support the thematic case. However, the binary nature—58% upside if the company survives versus 70% loss if capital markets close—demands position sizing below 5% of a portfolio and tolerance for illiquidity over 3–5 years. Conservative growth investors should avoid due to going concern risk.

Adherium supplies Bluetooth-enabled sensors that attach to asthma and COPD inhalers, monitoring when patients take their medication. The company earns recurring subscription revenue (A$100 per patient monthly) through US Medicare reimbursement codes, distributing devices via partnerships with allergy clinics and respiratory specialists. Revenue collapsed 74% in FY24 as legacy clinical trial contracts with AstraZeneca ended, bottoming at A$817,000 in FY25. The strategic pivot to recurring remote patient monitoring launched in Q4 FY25, with patient numbers reaching 600 by Q2 FY26. Recent results showed operational inflection: 4,666 devices shipped (versus 4,000 target), 103% quarter-on-quarter revenue growth, and partnerships now 70% activated.

The investment case rests on executing patient acquisition before the competitive window closes. The company needs to scale from 600 patients today to 8,000–12,000 (base case scenario) before Apple and Google achieve FDA medical-grade approvals in 2027–28, commoditising the device hardware. Capital remains the binding constraint—six months' cash runway requires another fundraise by mid-2026, with cumulative capital needs of A$18–20 million through 2029 diluting existing shareholders by 180%. The regulatory moat (14 FDA clearances plus clinical data) creates temporary differentiation, positioning for a strategic exit to established medtech companies at 1.5–3.0× revenue multiples.

At A$0.005 versus fair value A$0.0079, the stock is 58% undervalued.

What Happened

Q2 FY26 marked the operational inflection point following the strategic pivot. The company shipped 4,666 connected devices, exceeding the 4,000 target and validating manufacturing scale-up. Remote patient monitoring revenue grew 103% quarter-on-quarter, driven by 200 net patient additions monthly. Partnerships with Allergy Partners (130 clinic locations) and SENTA (80,000 eligible patients) reached 70% activation, meaning technology integration is complete and patient referrals are flowing. Gross margin remained negative at minus 14% due to fixed manufacturing support costs (A$655,000) not yet absorbed by patient volume. Capital structure deteriorated—the recent A$4 million raise at A$0.005 per share (67% discount to the prior round) expanded shares outstanding to 1.8 billion.

Key Metrics

What's Next

The trajectory depends on sustaining 200–400 patient additions monthly through 2027. Partnership conversion rates remain the critical unknown—current results show less than 1% of the 40,000 eligible patient pipeline converting, versus management's 2–3% target required to reach 8,000–12,000 patients. Margin inflection should begin in FY27 as patient volume absorbs fixed manufacturing costs and sensor purchasing power compresses unit costs from A$50 to A$35. The company requires capital raises in Q2–Q3 2026 (A$4–5 million) and again in 2027–2028, with pricing determining whether existing shareholders face 180% dilution (base case) or worse. Near-term catalysts include: Q3 FY26 results (January–February 2026) testing whether 400+ monthly patient adds are sustainable; CMS proposed rules (Q1 2026) revealing any threats to reimbursement code stability; and potential Apple Watch FDA submissions for respiratory monitoring, which would accelerate the commoditisation timeline. Strategic exit optionality improves as patient numbers cross 5,000–8,000 thresholds, attracting interest from established respiratory device manufacturers (ResMed, Omron) seeking to acquire FDA clearances and clinical data rather than building organically over 2–3 years.

The single biggest risk is capital depletion triggering liquidation. With six months' cash runway and negative equity of A$4.8 million, the company depends entirely on external capital to survive. The base case assumes successful fundraising (A$18–20 million total through 2029) at progressively worse terms, diluting current shareholders from 1.8 billion shares to 5.0 billion—even if the enterprise value grows to A$21.5 million, existing holders capture only A$0.0043 per share (14% loss from current price). The failure scenario (15% probability) activates if capital markets close—either due to investor fatigue (seven fundraises in 18 months already completed), execution disappointment (patient additions stalling below 150 monthly), or external shocks (reimbursement code restrictions, competitive displacement). Liquidation in Year 2 would recover approximately A$7 million (FDA clearances plus patient database), yielding A$0.0023 per share—a 54% loss. The going concern qualification in the audited accounts confirms this is not theoretical risk. Even in the success scenario (patient numbers reaching 15,000, strategic exit at 3.0× revenue), dilution to 4.0 billion shares means existing holders receive only A$0.0150—attractive on a percentage basis but dependent on surviving multiple capital raises at distressed pricing first.